Abstract
The Surface Plasmon Resonance Imaging (SPRI) sensor for papain determination based on the interaction between the immobilized cystatin and aqueous papain solution has been developed. The development of the sensor is a stage in the development of the sensor for the determination of cystein proteinases of the papain group. Cystatin was immobilized onto a gold chip by means of a thiol underlayer (cysteamine) and EDS/NHS reaction. Conditions of cystatin- papain interaction were optimized (pH, time of interaction and cystatin concentration). The developed sensor works within the range of 1 – 10 ng ml-1. However, the precision of measurements (RSD equal to 45%) should be improved. The response of the sensor to papain is specific. This was checked using BSA as a reference.
Keywords: surface plasmon resonance imaging, papain, cystatin
Protein & Peptide Letters
Title: The Surface Plasmon Resonance Imaging Sensor for Papain Based on Immobilized Cystatin
Volume: 14 Issue: 5
Author(s): E. Gorodkiewicz
Affiliation:
Keywords: surface plasmon resonance imaging, papain, cystatin
Abstract: The Surface Plasmon Resonance Imaging (SPRI) sensor for papain determination based on the interaction between the immobilized cystatin and aqueous papain solution has been developed. The development of the sensor is a stage in the development of the sensor for the determination of cystein proteinases of the papain group. Cystatin was immobilized onto a gold chip by means of a thiol underlayer (cysteamine) and EDS/NHS reaction. Conditions of cystatin- papain interaction were optimized (pH, time of interaction and cystatin concentration). The developed sensor works within the range of 1 – 10 ng ml-1. However, the precision of measurements (RSD equal to 45%) should be improved. The response of the sensor to papain is specific. This was checked using BSA as a reference.
Export Options
About this article
Cite this article as:
Gorodkiewicz E., The Surface Plasmon Resonance Imaging Sensor for Papain Based on Immobilized Cystatin, Protein & Peptide Letters 2007; 14 (5) . https://dx.doi.org/10.2174/092986607780782803
DOI https://dx.doi.org/10.2174/092986607780782803 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beneficial Effects of Plant Sources on the Treatment of Osteoporosis
Current Drug Targets Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammatory Mediators and the Failing Heart: A Translational Approach
Current Molecular Medicine Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides
Current Medicinal Chemistry Multi-target Activities of Selected Alkaloids and Terpenoids
Mini-Reviews in Organic Chemistry Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Regulation of Inflammatory Responses by Oxidized Phospholipids: Structure-Function Relationships
Current Pharmaceutical Design Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company
Current Drug Safety Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity
Current Medicinal Chemistry Accelerating Drug Discovery by Integrative Implementation of Laboratory Automation in the Work Flow
Current Medicinal Chemistry Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
Current Drug Therapy Interleukin-26, An Epitheliotropic T-Cell Cytokine
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Comparative Characterization of Experimental and Calculated Lipophilicity and Anti-Tumour Activity of Isochromanone Derivatives
Current Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Permeation Efficacy of a Transdermal Vehicle with Steroidal Hormones and Nonsteroidal Anti-inflammatory Agents as Model Drugs
Current Drug Delivery